5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D4 receptor antagonists(Dopamine D4 receptor antagonists)

Therapeutic Areas

Other Diseases

Active Indication

Sexual Dysfunctions, PsychologicalDecreased libido

Inactive Indication

Depressive Disorder

Originator Organization

Sprout Pharmaceuticals, Inc.

Active Organization

Valeant Canada S.E.C./Valeant Canada LP

Sprout Pharmaceuticals, Inc.

Inactive Organization-

License Organization

Bausch Health Cos., Inc.

Sprout Pharmaceuticals, Inc.

Searchlight Pharma, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (18 Aug 2015),

Sexual Dysfunctions, Psychological

RegulationPriority Review (United States)

Structure/Sequence

Molecular FormulaC20H21F3N4O

InChIKeyPPRRDFIXUUSXRA-UHFFFAOYSA-N

CAS Registry167933-07-5

Clinical Trials associated with Flibanserin

IRCT20210519051345N101

/ RecruitingNot Applicable

Bioequivalence study of Flibanserin 100 mg tablet manufactured by Zist Arvand Pharmed Compared to innovator product

Start Date05 May 2026

Sponsor / Collaborator-

NCT04743934

/ CompletedPhase 2IIT

RAD 2003/XUAB2104: Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.

Start Date02 Jul 2021

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT04002661

/ TerminatedPhase 2IIT

Hypoactive Sexual Desire Disorder in Males (10-18-40-13)

The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).

Start Date08 May 2020

Sponsor / Collaborator

Baylor College of Medicine

[+1]

100 Clinical Results associated with Flibanserin

100 Translational Medicine associated with Flibanserin

100 Patents (Medical) associated with Flibanserin

228

Literatures (Medical) associated with Flibanserin

01 Jan 2027·ANALYTICAL BIOCHEMISTRY

Integrated sustainability evaluation of electrochemical quantification of flibanserin and caffeine in various matrices

Article

Author: Mohamed, Tahany F ; Ali, Hazim M ; Abd El-Hadi, Heidi R ; Barghash, Sona S ; Atty, Shimaa A

Sustainable chemistry is increasingly used in pharmaceutical analysis to reduce environmental impact while improving laboratory personnel safety. This study describes the first sustainable electrochemical method for determining flibanserin (FLB) and caffeine (CAF) in various matrices, including bulk powder, pharmaceutical dosage form, and human plasma samples. FLB is used for the treatment of Hypoactive sexual desire disorder, while CAF may be co-administered with FLB as part of the therapeutic regimen, highlighting the need for reliable methods for their simultaneous determination. The experimental parameters were optimized using a zinc oxide nanoparticle polyethylene glycol -modified carbon paste electrode as working electrode at scan rate of 100 mV s^-1, and Britton-Robinson buffer (pH 7) as the supporting electrolyte using square wave voltammetry. Both analytes showed linear responses from 5.00 × 10^-7 M to 100.00 × 10^-7 M. The limits of detection for FLB and CAF were 1.617 × 10^-7 M and 1.265 × 10^-7 M, respectively. The limits of quantification were 4.851 × 10^-7 M for FLB and 3.795 × 10^-7 M for CAF. The method demonstrated satisfactory analytical performance and was validated in accordance with ICH guidelines. Student's t-test and F-test showed no significant differences between the proposed and reported methods. Sustainability was comprehensively evaluated using the Carbon Footprint Reduction Index, Multi-Color Assessment Tool, Analytical Green Star Area, and Click Analytical Chemistry Index. Overall, the proposed method provides a rapid, sensitive, and sustainable alternative for the simultaneous determination of FLB and CAF.

01 Jul 2026·Journal of Minimally Invasive Gynecology

Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer

Review

Author: Rojas, Kristin E ; Curran, Melissa ; Mihulka, Olivia ; Narasimhan, Raksha M ; Moore, Jessica F

OBJECTIVE:

Sexual dysfunction is a common but underrecognized sequelae of breast and gynecologic cancer treatment. Many patients experience symptoms of genitourinary syndrome of menopause, including vaginal dryness, dyspareunia, and diminished sexual desire. Addressing these challenges requires a comprehensive, evidence-based approach to management.

DATA SOURCES:

A comprehensive literature search was conducted using PubMed, Google Scholar, and Scopus to identify peer-reviewed studies published within the last 30 years. The search incorporated Medical Subject Headings and keywords related to sexual dysfunction and cancer survivorship, including terms such as "sexual dysfunction," "dyspareunia," "vaginal dryness," "vaginal hormone therapy," "breast cancer survivors," and "low desire."

METHODS OF STUDY SELECTION:

Studies were included if they examined sexual dysfunction in cancer patients or survivors, were published in English, and addressed either physiological or psychological aspects of sexual health. Articles were excluded if they lacked methodological rigor. An initial screening of titles and abstracts was followed by full-text review to determine relevance and inclusion.

TABULATION:

Findings were synthesized using thematic analysis, with studies grouped by cancer type, treatment modality, and impact on sexual function. Although no formal quality assessment tool was applied, emphasis was placed on high-impact studies and comprehensive reviews published in reputable journals.

INTEGRATION AND RESULTS:

Effective management of genitourinary syndrome of menopause includes nonhormonal options such as minimizing irritants, vaginal moisturizers, lubricants, the use of dilators, and pelvic floor therapies. Local hormonal therapies may offer relief for select patients depending on the hormone sensitivity of their cancer diagnosis. For low sexual desire, psychological and pharmacological agents such as bremelanotide and flibanserin have demonstrated efficacy. Vaginal lasers and compounded hormones pose significant risks to these patient populations and should be avoided. Multidisciplinary approaches, incorporating gynecologic, psychological, and oncologic expertise, are essential for optimizing patient outcomes.

CONCLUSION:

Sexual dysfunction following breast and gynecologic cancer requires individualized, multimodal management. A combination of nonhormonal and hormonal therapies, behavioral interventions, and emerging pharmacologic treatments offers promising avenues for improving sexual health and overall quality of life in survivors. Future research should focus on the effects of specific cancer therapies on sexual health, investigate the role of biological markers and dysfunction, and refine more personalized approaches to care.

14 May 2026·JOURNAL OF MEDICINAL CHEMISTRY

Dually Acting Ligands Targeting Serotonin Receptors: Implications in CNS Disorders

Review

Author: Popik, Piotr ; Grychowska, Katarzyna ; Trybała, Wojciech ; Zajdel, Paweł ; Malikowska-Racia, Natalia ; Nikiforuk, Agnieszka

The serotonergic system remains a critical focus of neuropsychopharmacology due to its widespread influence on mood, cognition, and behavior. Despite the clinical success of selective serotonin reuptake inhibitors (SSRIs), their long-term efficacy is limited by receptor heterogeneity, desensitization, and compensatory adaptations. Recent advances suggest that ligands simultaneously modulating two serotonin (5-HT) receptor subtypes may offer superior therapeutic outcomes. This perspective summarizes progress in developing such dually acting compounds for CNS disorders, including Alzheimer's and Parkinson's disease, schizophrenia, and mood disorders. Clinically relevant examples include flibanserin (5-HT_1A receptor agonist/5-HT_2A receptor antagonist), pimavanserin (5-HT_2A/5-HT_2C receptors inverse agonist), and eltoprazine (5-HT_1A/5-HT_1B receptors partial agonist), alongside experimental 5-HT_2A/5-HT₆, 5-HT₃/5-HT₆ or TAAR1/5-HT_2C receptors ligands. Integrating structure-activity insights and clinical findings, we discuss challenges of rational dual modulation. Advances in biased signaling, targeting distinctive conformational states, and optopharmacology utilizing photochromic ligands may further enable the design of innovative dually acting agents with improved efficacy and safety profiles.

News (Medical) associated with Flibanserin

29 Apr 2026

·www.prnewswire.com

SPROUT PHARMACEUTICALS, MAKERS OF ADDYI (FLIBANSERIN), NAMED ONE OF THE 10 MOST INFLUENTIAL HEALTH AND LIFE SCIENCE COMPANIES OF 2026 BY TIME

Sprout joins the ranks of biotech's biggest names following record-setting growth, expanding prescriber adoption, and increasing payer coverage RALEIGH, N.C., April 29, 2026 /PRNewswire/ -- TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the U.S. Food and Drug Administration approved an expanded indication for Addyi to include all women under 65 with Hypoactive Sexual Desire Disorder (HSDD), regardless of menopausal status, unlocking a significantly broader patient population and accelerating commercial expansion. Continue Reading Sprout has scaled Addyi into a nationally recognized brand with record-setting commercial growth, expanded prescriber adoption with 1000 new prescribers added each month and increased affordability and access. Addyi is now the #1 prescribed treatment* for frustrating low libido, women's most common sexual concern, and is backed by more than ten years of clinical and real-world patient data. TIME evaluated companies based on impact, innovation, ambition, and success—selecting just 10 companies in health and life sciences as industry leaders. Sprout now stands alongside global powerhouses like Novo Nordisk and Genentech, a reflection of both its operating performance and its role in expanding the boundaries of modern healthcare. "We built this company to challenge a system that told women to settle," said Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals, "To now be recognized by TIME alongside the biggest forces in biotech is proof of what we've always believed - that when you refuse to accept the status quo, you don't just join the industry, you change it." A special print issue featuring all TIME100 Companies Industry Leaders will be available on newsstands April 28. The full list is available now at: Press Contact: Sunshine Sachs Morgan & Lylis [email protected] About Sprout Pharmaceuticals Sprout Pharmaceuticals is leading a revolution in women's health, pioneering innovative treatments that address long-overlooked needs. With the launch of Addyi, the first ever FDA-approved treatment for Hypoactive Sexual Desire Disorder (HSDD), Sprout helped shift the conversation around women's sexual wellness. The company remains committed to advancing science, expanding access, and advocating for the care women deserve. About Addyi® (flibanserin) Addyi is the first FDA-approved prescription medication for the treatment of hypoactive sexual desire disorder (HSDD), now including all women under 65. It is a non-hormonal, once-daily pill prescribed by more than 30,000 U.S. healthcare professionals. Addyi is believed to work on key neurotransmitters involved in sexual desire and responsiveness although the exact mechanism of action of Addyi is unknown. Please see below for the indicated use of Addyi and Important Safety Information including important warnings regarding low blood pressure and fainting. Addyi is broadly accessible and affordable for most patients: women with insurance typically pay just $20 monthly, and for those paying cash, Addyi is available for $149 per month with free shipping through PHILRx mail-order pharmacy. Addyi is also available at more than 70,000 retail pharmacies nationwide, where patients can use a GoodRx coupon to lower out-of-pocket costs. Patients should consult with their healthcare provider to determine whether Addyi is appropriate for them. Learn more or start a telehealth visit today at Addyi.com. About Hypoactive Sexual Desire Disorder (HSDD) Hypoactive Sexual Desire Disorder (HSDD), also known as frustrating low libido, is a persistent lack of sexual interest or desire. It is the most common form of sexual dysfunction in women, impacting an estimated 40% of women according to the Mayo Clinic. What is ADDYI? ADDYI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women <65 years of age who have not had problems with low sexual desire in the past, no matter the type of sexual activity, situation, or sexual partner, and it is troubling to them. Their low sexual desire is not due to a medical or mental health problem, problems in the relationship, medicine or other drug use. ADDYI is not for use in men or to improve sexual performance. IMPORTANT SAFETY INFORMATION What is the most important information I should know about ADDYI? ADDYI can cause severe low blood pressure and fainting (loss of consciousness). Your risk is higher if you drink alcohol close to your dose. Do not take ADDYI with certain medicines or if you have liver problems. To lower your risk of low blood pressure and fainting: Do not drink alcohol close to the time you take ADDYI. Skip your dose if you had 3 or more drinks before bedtime. Wait at least 2 hours after 1–2 alcoholic drinks before taking ADDYI. After taking ADDYI, do not drink alcohol until the next day Talk to your doctor about the medicines and supplements you take and before starting any new ones Do not take ADDYI if you have liver problems If you feel dizzy or lightheaded after taking ADDYI, lie down right away. Get medical help if symptoms do not go away. Who should not take ADDYI? Do not take ADDYI if you: take certain medicines that increase ADDYI levels in your blood (including some treatments for HIV, fungal infections, antibiotics, hepatitis C, heart conditions, or depression such as nefazodone) have liver problems are allergic to ADDYI What should I tell my doctor before taking ADDYI? Tell your doctor about all your medical conditions, including if you: drink alcohol, use drugs, or have a history of substance abuse have ever had depression or other mental health conditions have low blood pressure or a condition that can cause it are pregnant, planning pregnancy, or breastfeeding Tell your doctor or pharmacist about all medicines and supplements you take, as they may interact with ADDYI. What should I avoid while taking ADDYI? Do not drink alcohol close to your dose Do not drive or operate machinery for at least 6 hours after taking ADDYI Do not drink grapefruit juice Do not take supplements such as St. John's Wort, ginkgo, or resveratrol, or certain medicines like cimetidine, without talking to your doctor What are the possible side effects of ADDYI? ADDYI can cause serious side effects, including: See "What is the most important information I should know about ADDYI?" Sleepiness low blood pressure and fainting The most common side effects include: dizziness nausea tiredness trouble sleeping dry mouth This is not a complete list of side effects. Call your doctor for medical advice. See Full Prescribing Information and Medication Guide, including important warnings regarding low blood pressure and fainting at Addyi.com/pi. * IQVIA Monthly Total Prescriptions Volume Data Comparing Addyi vs Vyleesi in the US. Sept 2022–March 2026 SOURCE Sprout Pharmaceuticals 21% more press release views with Request a Demo

Drug Approval

09 Jan 2026

·www.einpresswire.com

Analysis of WAC Price Changes Shows Modest Increases During Peak Adjustment Period

FAYETTEVILLE, NY, UNITED STATES, January 9, 2026 / EINPresswire.com / -- January is traditionally a peak period for pharmaceutical list price adjustments. The AnalySource team analyzed Wholesale Acquisition Cost (WAC) package pricing changes for all single-source prescription products with effective dates surrounding the new year, spanning December 1, 2025 through February 28, 2026. Overall, the analysis shows that most price changes were modest, though a limited number of notable outliers were observed. The analysis encompassed 1,902 National Drug Codes (NDCs) representing all identified single-source products with WAC package pricing changes during the analysis period. Only a small subset exhibited material pricing movement, with 11 drugs, some with various formulations, reporting WAC package price decreases and 31 products recording WAC package price increases of 10% or greater. These findings underscore that large price movements remain the exception rather than the norm, even during peak annual pricing cycles. Several significant outliers stood out in the data. Sandoz’s CIMERLI reported an 85.29% decrease in WAC package price, representing the largest reduction observed during the period. The largest WAC package price increase in the dataset was reported by PAI Holdings for TRIHEXYPHENIDYL (+480%). In addition, the most extreme WAC package price increases were highly concentrated within a small number of manufacturers, with Hospira/Pfizer accounting for the majority of increases exceeding 300%, including Verapamil HCl (+377%), Lorazepam (+346%), Naloxone HCl (+334%), and Hydromorphone HCl (+318%). These products are commonly used in hospital and acute care settings, where pricing dynamics may differ from those of outpatient or retail-dispensed therapies. Other notable movements included Sprout Pharmaceuticals, which reported a 110.64% increase for ADDYI, a branded product indicated for sexual function disorders. Novo Nordisk implemented substantial price decreases across multiple insulin products, including Fiasp and Tresiba presentations, reflecting a coordinated portfolio-level pricing adjustment rather than isolated product changes. Several manufacturers exhibited mixed pricing strategies within their portfolios. Boehringer Ingelheim reported modest price increases for products such as Ofev, Pradaxa, and Gilotrif while simultaneously implementing price decreases of approximately 44% for several other products. Pfizer reported both significant price increases across select hospital and specialty products and a price decrease for Xeljanz, a therapy used in inflammatory conditions. Outside of these exceptions, most manufacturers reported modest WAC package price increases in the range of 2% to 6%, consistent with historical annual pricing patterns. Across therapeutic areas, these adjustments align with routine pricing activity that may reflect product lifecycle stage, competitive dynamics, manufacturing considerations, and regulatory developments. While additional list price adjustments are expected later in the pricing cycle, early indications suggest that the majority of products will continue to reflect modest pricing changes, with large increases and decreases remaining relatively limited. The AnalySource team will continue to monitor these developments closely and will provide further updates as additional information becomes available. Daniel Miccio DMD America, Inc. +1 315-400-2289 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultFinancial Statement

08 Jan 2026

·www.prnewswire.com

PHIL and Sprout Pharmaceuticals Expand Their Affordable Direct-to-Patient Access Program for Addyi(flibanserin)

PHIL expands direct-to-patient access to Addyi for as low as $40 per year with commercial insurance coverage or $149 per month cash whether accessed through telehealth or a doctor's office. SCOTTSDALE, Ariz., Jan. 8, 2026 /PRNewswire/ -- PHIL, the technology-powered patient access platform designed to help patients get easy and affordable access to their prescribed medications, and Sprout Pharmaceuticals, today announced that they have expanded Sprout's direct-to-patient program for Addyi (flibanserin). Addyi has recently received an expanded indication from the FDA and is now approved to treat hypoactive sexual desire disorder (HSDD) in women less than 65 years of age. Addyi, an HSDD therapy developed by Sprout Pharmaceuticals, is made for women experiencing distressing low desire and is the only FDA-approved pill proven to increase a woman's sex drive in both premenopausal and postmenopausal women. The goal of the expanded direct-to-patient program is to help patients prescribed Addyi have a more accessible, convenient, and affordable path to start and remain on therapy. Addyi's robust direct-to-patient solution powered by PHIL, offers seamless medication access with telemedicine services, the lowest out-of-pocket cost for commercially insured and cash-pay patients, and free home delivery across the U.S. Through PHILRx, Addyi may cost as low as $40 per year with commercial insurance coverage or $149 per month for cash pay. All patients receive free home delivery. Healthcare providers can send prescriptions to PHILRx through their EMR. For more information, see phil.us/addyi. "The best patient experience begins with affordable access. We're incredibly proud of our partnership with PHIL because it ensures that women prescribed Addyi, whether through an in-office visit or telehealth, can obtain the medication at the right price. Today 80% of Addyi patients pay under $100 per month through PHILRx, with more than half paying $40 annually with insurance coverage. This program delivers on exactly what we set out to do, it removes longstanding barriers to access in women's sexual health," said Cindy Eckert, CEO of Sprout Pharmaceuticals. Whether prescriptions come from an in-office doctor or a telehealth provider, PHIL helps make the prescription experience simple, convenient, and affordable. Patients prescribed Addyi can receive their prescription on time and at their doorstep — with affordability support designed to help patients pay the lowest out-of-pocket cost available. Additionally, PHIL offers proactive refill support to help patients stay adherent to therapy. "Patients deserve a medication access experience that's as modern as the science," said Deepak Thomas, Founder & CEO of PHIL. "When a clinician decides Addyi is appropriate, PHIL helps remove barriers commonly found in traditional access challenges, with an affordability-first approach that's built around the patient." About PHIL/PHILRx PHIL is on a mission to improve patients' lives through innovative technology and dedicated support. The PHIL platform is designed to help more patients start and stay on therapy, quickly, easily and affordably. Learn more at . About Sprout Pharmaceuticals Sprout Pharmaceuticals is leading a revolution in women's health, pioneering innovative treatments that address long-overlooked needs. With the launch of Addyi, the first and only FDA-approved pill to treat low sexual desire (HSDD), Sprout helped shift the conversation around women's sexual wellness. The company remains committed to advancing science, expanding access, and advocating for the care women deserve. See full prescribing Information, including Boxed Warning regarding severe low blood pressure and fainting in certain settings at addyi.com/pi Media Contact: Alyssa Newby PANBlast for PHIL [email protected] SOURCE Phil 21% more press release views with Request a Demo

Drug Approval

100 Deals associated with Flibanserin

External Link

KEGG	Wiki	ATC	Drug Bank
D02577	Flibanserin	G02CX02	DB04908

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sexual Dysfunctions, Psychological	United States	Sprout Pharmaceuticals, Inc.	18 Aug 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Decreased libido	NDA/BLA	United States	Sprout Pharmaceuticals, Inc.	-
Depressive Disorder	Phase 3	United States	Sprout Pharmaceuticals, Inc.	01 Jan 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04743934 (RAD 2003, CTgov)	Phase 2	Adenocarcinoma of prostate	44	Androgen deprivation therapy+Flibanserin 100 MG (Flibanserin + ADT)	dudxczegmy = felbycfsyt ivlweyechw (yulnknykib, gzwsgcwivo - inqwjrfnnw) View more	-	20 Jul 2026
				Placebo (Placebo + ADT)	dudxczegmy = hyfozyifmc ivlweyechw (yulnknykib, cwndaotdsc - vecakgxtkx) View more
NCT02770768 (CTgov)	Not Applicable	Sexual Dysfunctions, Psychological	57	Flibanserin (Flibanserin)	jsjpfdzfol(ymahddcfhi) = femsiwjzpw npvcyziams (kntakvutjz, qqkmbsyngo - jsfiiyaden) View more	-	16 May 2024
				Placebo (Placebo)	jsjpfdzfol(ymahddcfhi) = usugkgpalj npvcyziams (kntakvutjz, jajghtrrmo - bprswdlfam) View more
NCT03707340 (ASCO2023)	Not Applicable	Breast Cancer Adjuvant	37	Flibanserin 100mg	uqaxfjpwza(pidogxuqaz) = oqnqxcrxpx piloezysyq (agpljaobld )	Positive	31 May 2023
NCT01057901 (PLUMERIA, Pubmed \| J Sex Med) Manual	Phase 3	Sexual Dysfunctions, Psychological	745	Flibanserin	cfkerpfuwo(raxllxfvgt): P-Value = 0.011 View more	Positive	01 Jun 2017
				Placebo
AUA2017	Not Applicable	-	-	Flibanserin	wbvsbiomtf(stsibueczg) = No serious adverse events were noted caefilervv (lblkplakac )	Positive	01 Apr 2017
NCT01040208 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological \| Depressive Disorder	111	flibanserin 50 mg to 100 mg qhs (Flibanserin 50 mg to 100 mg Qhs)	xqicuqmexa = zaphvxqzhm qynopfzbbs (mztjzvqcbk, uflazzrmsp - ngelgwtaoo) View more	-	24 Aug 2016
				flibanserin 100 mg qhs (Flibanserin 100 mg Qhs)	xqicuqmexa = ninyqwpegv qynopfzbbs (mztjzvqcbk, unadtrhzgf - ntkmgvbgmu) View more
NCT00360243 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological \| Decreased libido	1,385	flibanserin (Flibanserin 25 mg b.i.d)	vqqlsauhxa(otwqyeerjx) = icfeccltro uzrltqxyav (ugkicdicml, 3.4) View more	-	27 Jun 2016
				flibanserin (Flibanserin 50mg Qhs)	vqqlsauhxa(otwqyeerjx) = ofmswviabm uzrltqxyav (ugkicdicml, 4.2) View more
NCT00360555 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological	1,584	flibanserin	fzuneinojw(okkznmunfq) = shitqqtley xjvklonzjr (tfbyjwtrrz, 3.4) View more	-	27 Jun 2016
NCT00360529 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological \| Decreased libido	880	flibanserin	hpqcninxzt(hltkqwfbtc) = vvhheovpoc bjdkgzzooe (mophyywcem, 3.4) View more	-	27 Jun 2016
NCT00601367 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological	480	flibanserin flexible dose	lunwlenwra = mztjxjgzhm vodiexenfh (kqzqpcdifm, tkexurtgke - wuypxhjjqo) View more	-	20 Jun 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis